- Home
- SPRO vs BLUE Comparison
SPRO vs BLUE Comparison
Compare SPRO & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- BLUE
- Stock Information
- Founded
- SPRO 2013
- BLUE 1992
- Country
- SPRO United States
- BLUE United States
- Employees
- SPRO N/A
- BLUE N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPRO Health Care
- BLUE Health Care
- Exchange
- SPRO Nasdaq
- BLUE Nasdaq
- Market Cap
- SPRO 33.0M
- BLUE 36.9M
- IPO Year
- SPRO 2017
- BLUE 2013
- Fundamental
- Price
- SPRO $2.50
- BLUE $4.97
- Analyst Decision
- SPRO Buy
- BLUE Hold
- Analyst Count
- SPRO 4
- BLUE 7
- Target Price
- SPRO $5.00
- BLUE $44.60
- AVG Volume (30 Days)
- SPRO 10.8M
- BLUE 1.1M
- Earning Date
- SPRO 05-13-2025
- BLUE 05-14-2025
- Dividend Yield
- SPRO N/A
- BLUE N/A
- EPS Growth
- SPRO N/A
- BLUE N/A
- EPS
- SPRO N/A
- BLUE N/A
- Revenue
- SPRO $44,584,000.00
- BLUE $103,946,000.00
- Revenue This Year
- SPRO N/A
- BLUE $205.45
- Revenue Next Year
- SPRO N/A
- BLUE $3.74
- P/E Ratio
- SPRO N/A
- BLUE N/A
- Revenue Growth
- SPRO N/A
- BLUE 127.51
- 52 Week Low
- SPRO $0.51
- BLUE $3.20
- 52 Week High
- SPRO $2.80
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- SPRO 86.18
- BLUE 62.82
- Support Level
- SPRO $0.66
- BLUE $4.40
- Resistance Level
- SPRO $2.48
- BLUE $5.01
- Average True Range (ATR)
- SPRO 0.13
- BLUE 0.11
- MACD
- SPRO 0.20
- BLUE 0.06
- Stochastic Oscillator
- SPRO 86.36
- BLUE 96.72
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.